Jingjing Yu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jingjing Yu has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
- Wei Yan
Division of Nephrology and Kidney Research Institute, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China
3 shared publications - Zhenhua Shao
Division of Nephrology and Kidney Research Institute, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China
3 shared publications - Bowen Ke
Department of Anesthesiology, Laboratory of Anesthesia and Critical Care Medicine, National-Local Joint Engineering Research Centre of Translational Medicine of Anesthesiology, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China
2 shared publications - Chanjuan Xu
Cellular Signaling laboratory, International Research Center for Sensory Biology and Technology of MOST, Key Laboratory of Molecular Biophysics of MOE, College of Life Science and Technology, Huazhong University of Science and Technology, Wuhan, China
2 shared publications Dandan Chen
Functional and Molecular Imaging Key Laboratory of Sichuan Province, Department of Radiology, Huaxi MR Research Centre (HMRRC), West China Hospital of Sichuan University, Chengdu, China
2 shared publicationsFan Xia
Department of Neurosurgery, West China Hospital, Sichuan University, Chengdu, China
2 shared publications
Latest Publications
- Open Access
- 17 February 2026
- Published by Springer Nature in Nature
- Vol. 651 (8104) , E5
Publisher Correction: Psychedelics elicit their effects by 5-HT2A receptor-mediated Gi signalling
- 17 February 2026
- Published by Springer Nature in Nature
- Vol. 651 (8104) , E5
Open AccessPublisher Correction: Psychedelics elicit their effects by 5-HT2A receptor-mediated Gi signalling
- Top Cited Papers
- 28 January 2026
- Published by Springer Nature in Nature
- Vol. 651 (8106) , 829-837
Psychedelics elicit their effects by 5-HT2A receptor-mediated Gi signalling
Psychedelics are undergoing a renaissance as potential therapy for psychiatric disorders, with more than 200 clinical trials being studied across several countries1,2,3. However, the precise mechanisms by which these drugs bring about benefits and the potential clinical risks are not yet fully understood. The serotonin 2A receptor (5-HT2AR) was reported to be a Gq-coupled receptor and the primary interoceptive target of psychedelics4,5. Here we compared psychedelics and their non-hallucinogenic analogues (nHAs) using in vitro and in vivo approaches, finding that 5-HT2AR-mediated non-canonical Gi signalling is essential for hallucinogenic effect. We further presented five cryo-electron microscopy structures of 5-HT2AR–Gi/Gq in complex with psychedelics or nHAs. Structural analysis and pharmacological investigation revealed that a special contact between nHAs with 5-HT2AR mediated the signalling bias. Building on this insight, we identified a 2,5-dimethoxy-4-iodoamphetamine derivative, DOI-NBOMe, which exhibits potent and selective Gq-biased activity, and demonstrates promising therapeutic effects in mouse models without hallucinogenic effect. Our finding uncovers the functional mechanisms underlying the Gi signalling mediated by 5-HT2AR and provides valuable insights for designing psychedelic-based drugs with minimized risk from hallucinogenic effects.
- 28 January 2026
- Published by Springer Nature in Nature
- Vol. 651 (8106) , 829-837
Top Cited PapersPsychedelics elicit their effects by 5-HT2A receptor-mediated Gi signalling
Psychedelics are undergoing a renaissance as potential therapy for psychiatric disorders, with more than 200 clinical trials being studied across several countries1,2,3. However, the precise mechanisms by which these drugs bring about benefits and the potential clinical risks are not yet fully understood. The serotonin 2A receptor (5-HT2AR) was reported to be a Gq-coupled receptor and the primary interoceptive target of psychedelics4,5. Here we compared psychedelics and their non-hallucinogenic analogues (nHAs) using in vitro and in vivo approaches, finding that 5-HT2AR-mediated non-canonical Gi signalling is essential for hallucinogenic effect. We further presented five cryo-electron microscopy structures of 5-HT2AR–Gi/Gq in complex with psychedelics or nHAs. Structural analysis and pharmacological investigation revealed that a special contact between nHAs with 5-HT2AR mediated the signalling bias. Building on this insight, we identified a 2,5-dimethoxy-4-iodoamphetamine derivative, DOI-NBOMe, which exhibits potent and selective Gq-biased activity, and demonstrates promising therapeutic effects in mouse models without hallucinogenic effect. Our finding uncovers the functional mechanisms underlying the Gi signalling mediated by 5-HT2AR and provides valuable insights for designing psychedelic-based drugs with minimized risk from hallucinogenic effects.
- Open Access
- 5 February 2024
- Published by Wiley in Clinical and Translational Medicine
- Vol. 14 (2) , e1576
Elucidating the molecular pharmacology of trace amine‐associated receptor 1 to advance antipsychotic drug discovery
- 5 February 2024
- Published by Wiley in Clinical and Translational Medicine
- Vol. 14 (2) , e1576
Open AccessElucidating the molecular pharmacology of trace amine‐associated receptor 1 to advance antipsychotic drug discovery